Granules India Limited shareholders approved all proposed resolutions at the company’s 35th Annual General Meeting (AGM) held on August 6, 2026, endorsing a final dividend payout for FY25-26 and the re-appointment of an executive director. The meeting, conducted via video conferencing, saw robust participation with 67 members attending virtually and significant engagement through remote e-voting mechanisms.

The proceedings were chaired by Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, who delivered the opening address before transacting the business items. The meeting commenced at 11:30 A.M. and concluded at 12:34 P.M. As per Regulation 30 and Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted the voting results to the National Stock Exchange of India Limited and BSE Limited. The requisite quorum was present, allowing the meeting to proceed with the adoption of financial statements, dividend declaration, and director appointments.

Key Resolutions Passed

Shareholders voted on three ordinary resolutions during the AGM. All items received majority approval through a combination of remote e-voting and voting at the meeting. Ms. Priyanka Chigurupati, who retires by rotation, was re-appointed as a director following shareholder consent. The final dividend for the financial year ended March 31, 2026, was declared at Rs. 1.75 paise per equity share.

Voting Process and Scrutiny

The voting process was scrutinized by Dhanunjaya Kumar Alla, Partner at M/s. Dhanunjaya & Haranath, Chartered Accountants, Hyderabad, appointed as the Scrutinizer under Section 108 of the Companies Act, 2013. Remote e-voting was open from August 3, 2026, at 9:00 A.M. IST to August 5, 2026, at 5:00 P.M. IST. Members holding shares as of the record date, July 30, 2026, were eligible to vote. The total number of shareholders on the record date was 1,83,956.

KFin Technologies Limited provided the electronic voting system. Votes cast via remote e-voting were blocked for duplicate voting at the AGM. The results were unblocked after the conclusion of the meeting at 12:39 P.M. on August 6, 2026. The Scrutinizer’s report confirmed that all resolutions were passed with the requisite majority.

What the Numbers Show

The voting data indicates near-unanimous support for the company’s governance and financial proposals. With over 176 million votes cast across all resolutions, institutional and retail participation was high. The re-appointment of Ms. Priyanka Chigurupati received 99.69% support, reflecting strong confidence in the existing management structure. The minimal dissent in the financial statement adoption (less than 0.01% against) underscores shareholder alignment with the Board’s reporting and audit outcomes.

Granules India Limited reported a record profit after tax (PAT) of ₹1,800 Mn for Q1FY27, up 60% year-on-year, driven by a 22% revenue surge to ₹14,768 Mn and improved operational efficiency. The company achieved a net debt to EBITDA ratio of 0.07x, effectively becoming debt-free, while generating ₹3,874 Mn in operating cash flow. During the earnings call held on July 21, 2026, management highlighted strategic shifts toward complex generics and peptide contract development and manufacturing organization (CDMO) services as primary growth drivers.

Financial Performance and Cash Flow

Revenue from operations reached ₹14,768 Mn in Q1FY27, compared to ₹12,101 Mn in Q1FY26. EBITDA grew 37% to ₹3,389 Mn, with margins expanding to 22.9% from 20% in the prior year period. Profit before tax before exceptional items rose 41% to ₹2,404 Mn. Return on Capital Employed (ROCE) improved to 18.0% from 17.6% in FY26.

Net debt stood at ₹1,012 Mn, down significantly from ₹4,021 Mn at the end of FY26. Chief Financial Officer Mukesh Surana attributed the strong cash generation to reduced receivable days in the U.S. market and disciplined working capital management, which improved net working capital to sales to 29% from 30% in Q1FY26.

Strategic Focus: Peptides and Complex Generics

Complex generics now constitute 50% of Finished Dosages revenue, up from 39% a year ago. Chairman & Managing Director Dr. Krishna Prasad Chigurupati emphasized that the company is transitioning from a volume-driven model to an innovation-led platform. The peptide CDMO business, built around Senn Chemicals, grew more than 100% year-on-year. Chief Strategy Officer Sanjay Kumar stated that the intermediate milestone for the peptide platform is reaching $50 million in annual revenue with over 30% EBITDA margin within three years. For FY27, the target for the peptide segment is to turn profit-after-tax positive.

Capacity Expansion and Regulatory Updates

Management provided updates on key facilities. The Genome Valley facility (GLS), which adds approximately 40% to formulation capacity, is expected to cross 50% utilization by year-end. The U.S. facility, GPI, operates at 70% capacity with room for expansion. Regarding the Gagillapur facility (GGP), remediation work is essentially complete, with seven of eight facilities holding clean Establishment Inspection Reports (EIRs). Nine product launches are pending FDA clearance at GGP.

Capex and Future Outlook

Capex for Q1FY27 was ₹890 Mn, lower than Q4FY26’s ₹1,000 Mn due to the completion of the Genome Valley investment. Management reiterated its full-year capex guidance of ₹600 crore for the remainder of FY27. Additionally, initial estimates for the new peptide intermediate plant in Vizag suggest an investment of ₹100 crore, potentially scaling to ₹200 crore if expanded to API production. R&D expenses rose 30% to ₹880 Mn (6% of sales), focused on high-barrier areas such as CNS, oncology, and complex formulations.